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Introduction
Cytochrome P450 (P450)-dependent monooxygenases are a superfamily of hemecontaining enzymes that metabolize a wide variety of xenobiotics including many drugs (Johnson and Stout, 2005) . The importance of studies of P450 enzymes is bolstered by their critical role in steroid and prostaglandin synthesis in humans. P450 catalysis generally occurs through the insertion of an atom of molecular oxygen into an organic ligand, often in a regio-and stereoselective manner. However, these enzymes are also known for the remarkable plasticity that enables them to adapt to and accommodate a broad range of substrates of different size, shape, and stereochemistry (Domanski and Halpert, 2001a; Gay et al., 2010a) . As elucidated by crystallographic studies, substrate recognition in P450s is enabled through the repositioning of active site residues and other conformational changes (Williams et al., 2000) . The structural analysis of rabbit P450 2B4 in complex with the drugs ticlopidine and clopidogrel is a recent illustration of such side chain rearrangement in order to accommodate the respective ligands within the active site (Gay et al., 2010b) .
Human P450 2B6 metabolizes a large pool of clinically important drugs including bupropion, efavirenz, cyclophosphamide, selegiline, propofol, and artemisinin . Despite major advances in crystallization and structural biology of human P450 enzymes, direct structural information on P450 2B6 has remained scant. Moreover, the polymorphic nature of P450 2B6 results in several variants, including the most common single nucleotide polymorphisms (SNP) Q172H and K262R , that lead to differences in protein levels and/or activity among individuals. Detailed information on P450 2B6 structureactivity relationships will be required to understand the mechanisms of altered protein function.
This article has not been copyedited and formatted. The final version may differ from this version. Over the past decade, more than ten structures of P450 2B4, which shares 78% amino acid sequence identity with P450 2B6, were solved, revealing four different conformations.
These include two distinct ligand-free states of protein, open and closed, as well as other conformations observed in complex with various inhibitors and drugs (Gay et al., 2010a) . The crystal structures of the open ligand-free form and two inhibitor-bound complexes were in agreement with the conformational changes observed in solution in recent hydrogen-deuterium exchange mass spectrometry experiments (Wilderman et al., 2010) . Furthermore, the flexibile regions of 2B4 affected by ligand binding were consistent between the solution studies and x-ray crystal structures. Until recently, the structures of rabbit P450 2B4 served as a template for making homology models and for identifying key residues in human P450 2B6 Domanski and Halpert, 2001a) . The recently determined crystal structure of a P450 2B6 genetic variant in complex with 4-(4-chlorophenyl)imidazole (4-CPI) provided the detailed look at this human enzyme (Gay et al., 2010c) , which allowed for the comparison of two P450 2B structures from different species. Here, Y226H and K262R mutations were introduced into the wild type P450 2B6 construct with an N-terminal truncation and modifications. These internal mutations were made based on years of research efforts to improve the stability, solubility and yield of this enzyme, making it amenable for the high expression levels and purity required for crystallization (Hanna et al., 2000; Kumar et al., 2007; Mitsuda and Iwasaki, 2006; Scott et al., 2001 ).
To further our understanding of structure-function relationships in P450 2B6 and its role in drug metabolism and interactions, we solved the crystal structures of P450 2B6 in complex with the inhibitors 4-benzylpyridine (4-BP) and 4-(4-nitrobenzyl) pyridine (4-NBP). The in vitro inhibition potency of various pyridine inhibitors and other structurally unrelated compounds has This article has not been copyedited and formatted. The final version may differ from this version. been determined previously using 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) as the substrate with recombinant wild type 2B6 and also with human liver microsomes (Korhonen et al., 2007) .
From these studies 4-BP and 4-NBP were proposed as potent and selective P450 2B6 inhibitors of potential use in drug design and development (Korhonen et al., 2007) . Our study compares the structures of P450 2B6 complexes with 4-BP, 4-NBP, 4-CPI structure, enabling us to analyze specific reorientations of amino acid side chains to facilitate ligand binding within the mostly hydrophobic active site.
This article has not been copyedited and formatted. The final version may differ from this version. Protein expression and purification. Heterologous expression of P450 2B6 was done similarly to a previously described protocol (Scott et al., 2001 20% (v/v) glycerol, 10 mM BME, and 0.5 mM PMSF. After treatment with lysozyme (0.2 mg/mL), the suspension was again collected by centrifugation. The resulting spheroplasts were then resuspended in the buffer containing 500 mM potassium phosphate (pH 7.4 at 4 °C), 20%
(v/v) glycerol, 10 mM BME, and 0.5 mM PMSF, and were sonicated three times for 45s on ice.
The detergent CHAPS was then added at a final concentration of 0.8% (w/v) and the solution was allowed to stir for 90 min at 4 °C before subjecting it to ultracentrifugation for 45 minutes at 245,000 g in a Beckman Coulter Optima L-80 XP Ultracentrifuge using a Ti 50.2 rotor. The concentration of P450 in the supernatant was measured using the reduced CO difference spectra (Omura and Sato, 1964) .
Nickel-affinity chromatography was employed for the purification of histidine-tagged 2B6 performed in the presence of CHAPS. Protein bound to the Ni-NTA column was washed using buffer containing 100 mM potassium phosphate (pH 7.4 at 4 °C), 100 mM NaCl, 20%
(v/v) glycerol, 10 mM BME, 0.5 mM PMSF, 0.5% CHAPS, and 5 mM histidine. The protein was eluted using buffer containing 10 mM potassium phosphate (pH 7.4 at 4 °C), 100 mM NaCl, 20% (v/v) glycerol, 10 mM BME, 0.5 mM PMSF, 0.5% CHAPS, and 50 mM histidine. The pooled P450-containing fractions were collected and then loaded onto a Macroprep CM column.
The column was washed using the buffer containing 20 mM NaCl, and the protein was eluted with high-salt buffer containing 50 mM potassium phosphate (pH 7.4 at 4 °C), 500 mM NaCl, 20% (v/v) glycerol, 1 mM EDTA and 0.2 mM DTT. Protein fractions containing the highest A 417 /A 280 ratios were pooled and the P450 concentration was measured using the reduced CO difference spectra (Omura and Sato, 1964) .
Crystallization and Data Collection. Two ml of the pooled purified protein (150 µM) was diluted to 18 µM in 50 mM potassium phosphate, pH 7.4, 500 mM sucrose, 500 mM NaCl, MOL #74427 Crystals were flash-frozen in liquid nitrogen, and the crystallographic data were collected remotely at Stanford Synchrotron Radiation Laboratory (SSRL) beamline 11-1 (Soltis et al.,
2008) using 0.5° oscillations over 180 frames and 10-s exposures. Crystals of 2B6 in complex with 4-BP and 4-NBP diffracted to 2.1 Å and 2.8 Å, respectively, and the data were integrated using iMOSFLM (Leslie, 1999) and scaled via SCALA in CCP4 (Bailey et al., 1994) (Table 1) .
Structure Determination and Refinement. Structure solutions were suggested using the automated molecular replacement pipeline Balbes (Long et al., 2008) . Clearly defined unbiased electron density for each of the respective ligands was observed in maps based on the individual output models from Balbes. Library descriptions for the ligands were created using the PRODRG server (van Aalten et al., 1996) . The Matthews' coefficient suggested the presence of one molecule in the asymmetric unit for the 2B6-4-BP structure and six molecules in the asymmetric unit for the 2B6-4-NBP structure. The output models from Balbes were further subjected to iterative model building with COOT (Emsley and Cowtan, 2004) using Fo-Fc and 2Fo-Fc electron density maps contoured at 3σ and 1σ, respectively. Water and Cymal-5 molecules were located and added manually, and REFMAC5 (Murshudov et al., 1997) was used for a rigid body and a restrained refinement until the completion of the model (Table 1) . The final models were validated using the program MOLPROBITY (Davis et al., 2004) , and the overall geometry ranked in the 94 th percentile for the 4-BP complex and 98 th percentile for the 4-NBP complex among structures of comparable resolution. Atomic coordinates and structure factors for the individual structures were deposited in the Protein Data Bank (PDB entries 3QOA
and 3QU8 for the 4-BP and 4-NBP complexes, respectively).
This article has not been copyedited and formatted. The final version may differ from this version. Spectral studies of 4-BP and 4-NBP binding to 2B6. Titrations were performed in buffer containing 50 mM potassium phosphate, pH 7.4, 500 mM NaCl, 1 mM EDTA, 0.2 mM DTT and 500 mM sucrose. Inhibitors (4-BP or 4-NBP) were dissolved in acetone, and the total solvent concentration maintained in the titration experiments was less than 1%. Difference spectra were recorded at room temperature after the addition of the inhibitor (100 µM stock concentration) to buffer containing 1 µM P450 in a 1-ml reaction volume on a S2000 single channel charge-coupled device rapid scanning spectrophotometer (Ocean Optics, Inc, Dunedin, FL.) using a 1-cm glass cuvette with a magnetic stirring compartment (Hellma USA, Plainview, NY) as described previously (Gay et al., 2010b) . To determine the spectral binding constants (K D ) of these high affinity inhibitors, the data were fit to the "tight binding" equation:
], where Δ A was the difference in absorbance between the maxima and minima, [E 0 ] and [I 0 ] are total enzyme and total inhibitor concentrations, respectively (Segel, 1975) .
IC 50 determinations. 7-EFC O-deethylation to the metabolite 7-hydroxy-4-trifluoromethylcoumarin (7-HFC) was measured using a fluorometric assay. The reconstituted system contained the following recombinant proteins at a molar ratio of 1:4:2; 2B6, rat cytochrome P450 reductase (CPR) (Harlow and Halpert, 1997) and rat cytochrome b 5 (Holmans et al., 1994) . The respective inhibitors were dissolved in acetone, and the total solvent content was maintained below 1% in the reaction mixture. Each 100-µl reaction mixture contained 50 mM HEPES, pH 7.4, 15 mM MgCl 2 , 10 pmol P450, 40 pmol CPR, 20 pmol cytochrome b 5 , 50 µM 7-EFC, and 0-100 μM of either 4-BP or 4-NBP. NADPH was added to initiate the reaction after 5 min of pre-incubation at 37 °C. The reactions were terminated by adding 20% trichloroacetic acid (TCA) after 5 minute of incubation. A control experiment was performed by This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Structure of 2B6 (Y226H/K262R) in complex with 4-BP. The 2B6-4-BP complex crystallized in the P3 2 21 space group with one molecule in the asymmetric unit. The structure of 2B6-4-BP was determined using Balbes, which used the structure of the 2B4-clopidogrel complex (Gay et al., 2010b ) as the search model from the PDB database (PDB ID code 3ME6).
The 2B6-4-BP output model was modified to reflect the amino acid differences between the 2B4 and 2B6 sequences. The inhibitor 4-BP with the pyridine nitrogen bound to the heme iron was clearly defined in an unbiased electron density map, and the inhibitor was modeled just prior to the final rounds of refinement ( Figure 1A ). The iterative process of model building and refinement using COOT and REFMAC5 resulted in a final R-factor and R-free of 19.7% and 24.9%, respectively (Table 1 ). The crystal structure of P450 2B6 bound to 4-BP is shown in Figure 1B . The protein residues from Gly28 through the first residue of the C-terminal, engineered 4 X His tag (His492) were ordered except for the stretch from Phe136 to Arg140.
Moreover, the mutations Y226H and K262R, which were introduced for enhanced solubility and stability, as described previously (Gay et al., 2010c) , were also clearly defined in the electron density. As observed in the 2B6-4-CPI complex, the polymorphic mutation K262R forms hydrogen bonds with residues Thr255 and Asp266 to possibly help stabilize the G/H loop. The model also contains 249 water molecules and 2 partially occupied molecules of Cymal-5. The density for the maltose group was not observed for one Cymal-5 molecule located near Phe220
and Phe223, and the density for only the cyclohexane ring was observed for the other molecule of Cymal-5 in the hydrophobic pocket near residues Leu43, Val212, and Leu216. group. Balbes selected the 2B6-4-CPI complex (Gay et al., 2010c) as the most closely related structure from the PDB database (PDB ID code 3IBD). Unbiased electron density from REFMAC5 clearly showed 4-NBP bound to the heme iron in chain B ( Figure 1C ). However, in the other five copies 4-NBP displayed varying degrees of disorder with partial density for the inhibitor. Density for the anionic nitro group of 4-NBP was not present in chains D and E, and the density for the nitrobenzyl moiety was missing in chains A and C. The density for 4-NBP was the poorest in chain F, and the ligand was not modeled in the active site. In spite of these differences in the degree of order of 4-NBP, the six copies of the protein were very similar (RMSD of 0.144 Å in a Cα overlay). The crystal structure of 2B6-4-NBP is shown in Figure   1D .
Overall, residues from Gly28 to His492 were observed in the final model in chains A, B, C, D and E, while chain F consisted of residues Gly28 to Ile486. As in the 4-BP structure, residues from Phe136 to Arg140 were disordered in each chain of this structure. Interestingly, these residues lie within the C-D loop region of 2B6, which was previously reported to interact with cytochrome P450 reductase (Bumpus and Hollenberg, 2010) . Arg262 was observed interacting with the same residues as in the 2B6-4-BP and 2B6-4-CPI structures. Phe108 in the 2B6-4-NBP structures, respectively. The heterocyclic nitrogen of the pyridine ring bound to heme in the 2B6-4-BP structure, rotates by about 90° in the 2B6-4-NBP structure.
Comparison
Moreover, the benzyl group of 4-NBP shifts by about 40° to accommodate the additional polar nitro group, and this displaces residue Phe108 away from its observed location in the 2B6-4-BP structure ( Figure 2A ). Such positioning of the nitro benzyl group of 4-NBP allows for inclusion of an additional active site residue, Phe108 located within the 5 Å radius from the ligand. The lack of any hydrogen bonding partners to interact with the nitro group could help explain the poor electron density observed for the nitro and nitro-benzyl groups in chains A, C, D, E, and F in the 2B6-4-NBP structure. Furthermore, small movements of residues Phe108, Phe115, Phe206, Phe292 and Phe297 compared with the 2B6-4-BP structure result in an increase of active site cavity volume from 279 Å 3 in the 2B6-4-BP to 344 Å 3 for 2B6-4-NBP, as calculated by VOIDOO (Kleywegt and Jones, 1994) . The change in cavity volumes resulted mainly from the movement of the above residues to accommodate the bulkier 4-NBP ligand in the active site.
However, the side chain of Leu362 in the 2B6-4-BP structure also protrudes by about 90° towards the active site and pushes Thr302 in close proximity to the pyridine ring of 4-BP ( Figure   2A ), which further reduces the active site cavity volume in the 2B6-4-BP structure. In the 2B6-pyridine inhibitor complexes, Val104, Phe115 and Glu301 are located within a 5 Å radius of the ligand, but were found slightly outside of this radius in the 2B6-4-CPI structure.
Additionally, the side chain of Glu301 in the 2B6-4-BP and 4-NBP structures flips out of the active site and contacts a water molecule as seen in the 2B6-4-CPI structure.
Spectral binding and enzyme inhibition studies. Addition of 4-BP and 4-NBP yielded
type II difference spectra with a peak at 423 nm and trough at 411 nm. The "tight binding (Table 2) . Moreover, the K D values obtained with this 2B6 (Y226H/K262R) mutant used for crystallization were similar to those previously determined in wild type 2B6 . The IC 50 values for inhibition of 2B6-catalyzed 7-EFC O-deethylation were 0.18 µM for BP and 0.09 µM for NBP (Table 2) , which correspond well with the previously observed values using wild type cDNA expressed 2B6 (Korhonen et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
Until recently, crystallographic studies of P450 2B enzymes were mainly focused on rabbit 2B4 due to its optimal solubility and stability during purification and crystallization. A series of crystal structures of 2B4 identified the active site residues that are involved in substrate recognition and ligand binding. In the closed structures of 2B4 in complex with 4-CPI and 1-CPI residues contacting the ligand include Ile101, Val104, Ile114, Phe115, Phe206, Ile209, Phe297, Ala298, Glu301, Thr302, Ile362, Val367 and Val477, which are mainly hydrophobic except for Glu301 and Thr302 (Scott et al., 2004; Zhao et al., 2007) . 2B6-4-CPI structure, Phe108 shifts towards the G-helix to accommodate the movement of Phe115. The benzyl group of 4-BP points toward residue Phe115 in the active site, while the addition of the nitro group in 4-NBP repositions this ligand, which points toward Phe108 on the B'-helix. Interestingly, the polarity of the nitro group in 4-NBP did not result in any major rearrangement of residues, but only side chain adjustments in the structure including that of Phe108 located opposite to the I-helix, suggesting that ligand binding is based solely on hydrophobicity, size and shape.
Among the other phenylalanine residues in the active site, Phe206 and Phe297, which were previously shown to be involved in substrate recognition, adopt conformations similar to those observed in the 2B4-1-CPI, 2B4-clopidogrel and 2B4-tBPA structures, where Phe206 moves into the active site and Phe297 moves out. In the 4-BP and 4-NBP structures, this prevents the large aromatic side chains from clashing with the pyridine inhibitors ( Figure 3 ). This is in contrast to the 2B6-4-CPI structure, and also 2B4-4CPI, 2B4-ticlopidine and the closed ligand-free 2B4 structures, where these two Phe residues orient themselves in the opposite fashion (Gay et al., 2010a) . Interestingly, substitution of Phe304 in P450 3A4, which is equivalent to Phe297 in P450s 2B, with either alanine or tryptophan has been shown to increase progesterone hydroxylation (Domanski et al., 2000; Domanski et al., 1998) . In P450 2B1, which shares 78% sequence identity with 2B6, only tryptophan substitution yielded a metabolite profile similar to wild type 2B1, suggesting that an aromatic ring is required at this location for normal substrate binding (Domanski and Halpert, 2001a) . The substitution of alanine for Phe297 in 2B1 also decreased the production of the predominant 7-hexoxycoumarin metabolite (7-(5-hydroxyhexoxy) coumarin) to half of that seen in wild-type (Domanski and Halpert, 2001a) . the smaller and more flexible leucine residue. This study reported decreased steroid hydroxylation and altered androstenedione and testosterone profiles, with increased progesterone oxidation (He et al., 1994) . This F206L mutation was also shown to reduce the rates of alkoxycoumarin O-dealkylation compared to wild type 2B1 (Kobayashi et al., 1998) , while F206A in 2B4 showed significantly lower activity towards 7-EFC and thermodynamically unfavorable ligand binding to 1-CPI than the 2B4 wild type enzyme .
From the structural alignment of active site residues in Figures 2A and 2B Leu362 has not been observed to interact with ligands in any of the previously solved 2B4 or 2B6 structures. However, Leu362 has been analyzed earlier in 2B1, and the substitution with either alanine or phenylalanine caused a dramatic loss in overall activities including steroid and 7-alkoxycoumarin oxidation (Domanski et al., 2001b) . Moreover, the corresponding aligned amino acid residue 365 in the closely related P450 2A4 and 2A5 enzymes is important for the ability to hydroxylate coumarin, and any mutant at this position has exhibited altered substrate specificity (Lindberg and Negishi, 1991) .
The active site residue Glu301, with its polar side chain, contributes to ligand binding in the 2B subfamily as evidenced by structural studies. Glu301 in the 2B4-4-CPI structure This article has not been copyedited and formatted. The final version may differ from this version. protrudes from the I-helix towards 4-CPI, where it interacts with the free azole nitrogen of the inhibitor (Scott et al., 2004) . In contrast, in the 2B4-1-CPI, 2B4-tBPA (closed) and 2B4-ticlopidine complexes, the same residue moves out of the active site and interacts with His172
( Figure 4A ) (Gay et al., 2010c) . In all three 2B6 complexes, Glu301 also flips out of the active site and interacts with Gln172 ( Figure 4B ). In the 2B6-4-BP and 2B6-4-CPI structures, Glu301 also interacts with trapped water molecules (waters are not resolved in the 2B6-4-NBP structure) ( Figure 4B ). It is noteworthy that the water molecule interacting with Glu301 also contacts the nearby Ser304. Interestingly, Ser304 is highly conserved among the 2B subfamily of enzymes ( Figure 5 ), as well as in other human P450s including 3A4. Consequently, a hydrogen bonding network is conserved for the flipped out conformation of Glu301 that involves direct interaction of Ser304 with His172 in 2B4 and water-mediated interaction when Gln172 is present in 2B6
( Figures 4A, 4B ). The lack of direct hydrogen bonding involving Ser304 in 2B6 may weaken the interaction of the E and I helices and influence the orientation of active site residues on the Ihelix. Moreover, residue 172, which is in close proximity to the active site, is the location of a known 2B6 SNP, resulting in a Q172H substitution . Previous studies involving 2B6 Q172H have shown decreased catalytic activity for bupropion hydroxylation and efavirenz metabolism compared with the wild type . Additionally, in most carriers, Q172H is associated with another major SNP, K262R, and the Q172H/K262R variant has shown decreased 2B6 activity and increased plasma concentration of the drug (Desta et al., 2007) .
To conclude, the crystal structures of 2B6 in complex with the potent and selective helices that also include residues within the active site. 
